L
Luca Faloppi
Researcher at University of Cagliari
Publications - 104
Citations - 2176
Luca Faloppi is an academic researcher from University of Cagliari. The author has contributed to research in topics: Sorafenib & Cancer. The author has an hindex of 25, co-authored 101 publications receiving 1849 citations. Previous affiliations of Luca Faloppi include Marche Polytechnic University.
Papers
More filters
Journal ArticleDOI
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Mario Scartozzi,Luca Faloppi,Gianluca Svegliati Baroni,Cristian Loretelli,Fabio Piscaglia,Massimo Iavarone,Pierluigi Toniutto,Giammarco Fava,Samuele De Minicis,Alessandra Mandolesi,Maristella Bianconi,Riccardo Giampieri,Alessandro Granito,Floriana Facchetti,Davide Bitetto,Sara Marinelli,L. Venerandi,Sara Vavassori,S. Gemini,Antonietta D'Errico,Massimo Colombo,Luigi Bolondi,Italo Bearzi,Antonio Benedetti,Stefano Cascinu +24 more
TL;DR: Once prospectively validated, the analysis of VEGF and VEGFR SNPs may represent a clinical tool to better identify HCC patients more likely to benefit from sorafenib.
Journal ArticleDOI
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
Mario Scartozzi,Riccardo Giampieri,Elena Maccaroni,M. Del Prete,Luca Faloppi,Maristella Bianconi,Eva Galizia,Cristian Loretelli,L. Belvederesi,Alessandro Bittoni,Stefano Cascinu +10 more
TL;DR: Bvacizumab seemed capable of improving clinical outcome in this specific group of patients who usually present with an adverse natural history, and the improved response rate also suggests a role for LDH as a predictive marker.
Journal ArticleDOI
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
Andrea Casadei Gardini,Emanuela Scarpi,Luca Faloppi,Mario Scartozzi,Nicola Silvestris,Daniele Santini,Giorgio de Stefano,Giorgia Marisi,Francesca Negri,Francesco Giuseppe Foschi,Martina Valgiusti,Giorgio Ercolani,Giorgio Ercolani,Giovanni Luca Frassineti +13 more
TL;DR: The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib and remained an independent prognostic factor for OS after adjusting for clinical covariates.
Journal ArticleDOI
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
Luca Faloppi,Mario Scartozzi,Maristella Bianconi,Gianluca Svegliati Baroni,Pierluigi Toniutto,Riccardo Giampieri,Michela Del Prete,Samuele De Minicis,Davide Bitetto,Cristian Loretelli,Marco D'Anzeo,Antonio Benedetti,Stefano Cascinu +12 more
TL;DR: LDH seemed able to predict clinical outcome in terms of PFS and OS for HCC patients treated with sorafenib, and it can speculate that patients with high LDH pretreatment levels may be optimal candidates for other emerging therapeutic agents or strategies targeting different molecular pathways.
Journal ArticleDOI
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
Mario Scartozzi,Maristella Bianconi,Luca Faloppi,Cristian Loretelli,Alessandro Bittoni,M. Del Prete,Riccardo Giampieri,Elena Maccaroni,S. Nicoletti,Luciano Burattini,Daniele Minardi,G Muzzonigro,Rodolfo Montironi,Stefano Cascinu +13 more
TL;DR: Patients with TT polymorphism of rs833061, CC polymorphisms of rs699947, CC allele of rs2010963 and CG polymorphismof rs6877011 seem to have a worse progression-free survival and overall survival when receiving first-line sunitinib.